Merck recognized on Fortune’s 2022 change the World List

This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.

AGC begins study to expand its Bio-CDMO capability in Japan

Fluor bags award for Biologics manufacturing facility in Scandinavia

Construction is now underway with the facility scheduled to be operational by 2025

Moderna creates new executive committee role for product launches

Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion

Dr VK Paul delivers lecture at NITI Aayog’s First India Development Strategies Lecture Series

Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic

Cadila and CII launches joint national campaign for rabies-free India by 2030

Rabies claims around 59,000 deaths globally a year, of which around 20,000 or just over one-third of the deaths take place in India alone

Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19

Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial

We will vaccinate 100% of the animals by 2025: Narendra Modi

The Prime Minister addressed a major problem that is affecting the income of farmers which is the diseases of animals and emphasised that in this direction India is working towards universal vaccination of animals

Merck invests € 130 million + to strengthen manufacturing capabilities in France

Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025

Lonza and Touchlight collaborate on end-to-end mRNA offering

Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology